

World Journal of *Gastroenterology*

World J Gastroenterol 2017 October 7; 23(37): 6747-6922



**EDITORIAL**

- 6747 Microbial dysbiosis in spouses of ulcerative colitis patients: Any clues to disease pathogenesis?
Sorrentino D

REVIEW

- 6750 Road to stemness in hepatocellular carcinoma
Flores-Téllez TNJ, Villa-Treviño S, Piña-Vázquez C
- 6777 Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction
Pasarin M, Abalde JG, Liguori E, Kok B, La Mura V
- 6788 Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review
Rahman MM, Mahadeva S, Ghoshal UC

ORIGINAL ARTICLE**Basic Study**

- 6802 Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis
Iyer JK, Kalra M, Kaul A, Payton ME, Kaul R
- 6817 Glycosylation-related gene expression in HT29-MTX-E12 cells upon infection by *Helicobacter pylori*
Cairns MT, Gupta A, Naughton JA, Kane M, Clyne M, Joshi L
- 6833 STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury
Abe M, Yoshida T, Akiba J, Ikezono Y, Wada F, Masuda A, Sakaue T, Tanaka T, Iwamoto H, Nakamura T, Sata M, Koga H, Yoshimura A, Torimura T
- 6845 Performance verification and comparison of TianLong automatic hypersensitive hepatitis B virus DNA quantification system with Roche CAP/CTM system
Li M, Chen L, Liu LM, Li YL, Li BA, Li B, Mao YL, Xia LF, Wang T, Liu YN, Li Z, Guo TS

Case Control Study

- 6854 Association of insertion-deletions polymorphisms with colorectal cancer risk and clinical features
Marques D, Ferreira-Costa LR, Ferreira-Costa LL, Correa RS, Borges AMP, Ito FR, Ramos CCO, Bortolin RH, Luchessi AD, Ribeiro-dos-Santos A, Santos S, Silbiger VN

Retrospective Cohort Study

- 6868 Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy

Seraj SM, Campbell EJ, Argyropoulos SK, Wegermann K, Chung RT, Richter JM

- 6877 Measurement of biological age may help to assess the risk of colorectal adenoma in screening colonoscopy

Kim SJ, Kim BJ, Kang H

Retrospective Study

- 6884 Prognostic factors of response to endoscopic treatment in painful chronic pancreatitis

Tantau A, Mandrutiu A, Leucuta DC, Ciobanu L, Tantau M

- 6894 *In vivo* histological diagnosis for gastric cancer using endocytoscopy

Tsurudome I, Miyahara R, Funasaka K, Furukawa K, Matsushita M, Yamamura T, Ishikawa T, Ohno E, Nakamura M, Kawashima H, Watanabe O, Nakaguro M, Satou A, Hirooka Y, Goto H

CASE REPORT

- 6902 Achalasia after bariatric Roux-en-Y gastric bypass surgery reversal

Abu Ghanimeh M, Qasrawi A, Abughanimeh O, Albadarin S, Clarkston W

- 6907 Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication

Semb S, Helgstrand F, Hjørne F, Bytzer P

- 6911 Rupture of small cystic pancreatic neuroendocrine tumor with many microtumors

Sagami R, Nishikiori H, Ikuyama S, Murakami K

LETTERS TO THE EDITOR

- 6920 Resistance of *Helicobacter pylori* to furazolidone and levofloxacin: A viewpoint

Zamani M, Rahbar A, Shokri-Shirvani J

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Toru Mizuguchi, MD, PhD, Associate Professor, Surgeon, Department of Surgery, Surgical Oncology and Science, Sapporo Medical University Hospital, Sapporo 060-8543, Hokkaido, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Yan Huang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Li-Juan Wei*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF

Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
October 7, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.


SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>



Resistance of *Helicobacter pylori* to furazolidone and levofloxacin: A viewpoint

Mohammad Zamani, Arash Rahbar, Javad Shokri-Shirvani

Mohammad Zamani, Student Research Committee, Babol University of Medical Sciences, Babol 47176-47745, Iran

Mohammad Zamani, Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol 47176-47745, Iran

Arash Rahbar, Student Research Committee, Babol University of Medical Sciences, Babol 47176-47745, Iran

Javad Shokri-Shirvani, Department of Internal Medicine, Babol University of Medical Sciences, Babol 47176-47745, Iran

ORCID number: Mohammad Zamani (0000-0003-1916-3873); Arash Rahbar (0000-0002-1935-2247); Javad Shokri-Shirvani (0000-0002-2090-2234).

Author contributions: Zamani M and Shokri-Shirvani J contributed in study design; Zamani M and Rahbar A drafted the manuscript; Shokri-Shirvani J revised the manuscript for important intellectual content; All authors have read the manuscript and approved its final version.

Conflict-of-interest statement: The authors declared no conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Javad Shokri-Shirvani, MD, Department of Internal Medicine, Babol University of Medical Sciences, Ganjafrooz Street, Babol 47176-47745, Mazandaran, Iran. j.shokri@mubabol.ac.ir
Telephone: +98-11-32199592
Fax: +98-11-32190971

Received: June 29, 2017

Peer-review started: June 30, 2017

First decision: July 13, 2017

Revised: July 30, 2017

Accepted: August 15, 2017

Article in press: August 15, 2017

Published online: October 7, 2017

Abstract

In their review, Arslan *et al*^[1] did not describe the status of *Helicobacter pylori* (*H. pylori*) treatment with furazolidone and the resistance to this antibiotic. We have presented different surveys showing the resistance of *H. pylori* to furazolidone from Asia and South America. The resistance rates varied but were mostly low (< 5%). There are not enough data on its efficacy and resistance in the United States and Europe. *H. pylori* mutations occurring in the *oorD* gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the *porD* gene, including G353A, A356G, C357T, C347T, C347G and C346A, have been indicated to be possibly related to the observed resistance. Additionally, to complete Arslan *et al*'s statement regarding levofloxacin resistance, it should be noted that compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the *gyrA* gene for the first time. However, the results on these topics are not sufficient, and more worldwide studies are suggested.

Key words: Susceptibility; Furazolidone; *Helicobacter pylori*; Resistance; Levofloxacin; Treatment

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We have presented different surveys showing the resistance of *Helicobacter pylori* (*H. pylori*) to furazolidone from Asia and South America. The resi-

Table 1 Studies evaluating the *Helicobacter pylori* resistance to furazolidone

Continent	Country	Study year	Strains (n)	Method	Resistance (%)	Author
Asia	China (Shanghai)	2000-2009	293	Agar dilution	0	Sun <i>et al</i> ^[6]
	China (Zhejiang)	2010-2012	21	Agar dilution	0.1	Su <i>et al</i> ^[7]
	China (Zhejiang)	2009-2014	9687	Agar dilution	< 0.01	Ji <i>et al</i> ^[8]
	India (Ghaziabad and New Delhi)	NA	68	Agar dilution	22.1	Gehlot <i>et al</i> ^[9]
	India (Gujarat)	2008-2011	80	Disk diffusion	13.8	Pandya <i>et al</i> ^[10]
	Iran (Rasht)	2012-2014	169	Disk diffusion	61.9	Maleknejad <i>et al</i> ^[11]
	Iran (Shiraz)	2004-2005	106	Agar dilution	9.4	Kohanteb <i>et al</i> ^[12]
	Iran (Sari)	2009	197	Disk diffusion	61.4	Abadi <i>et al</i> ^[13]
	Iran (Tehran)	2001-2004	135	Disk diffusion	0	Siavoshi <i>et al</i> ^[14]
	Iran (Tehran)	2002-2003	24	Disk diffusion	0	Fallahi <i>et al</i> ^[15]
	Iran (Tehran)	2005-2008	110	Disk diffusion	4.5	Siavoshi <i>et al</i> ^[16]
	Iran (Tehran)	2007-2008	104	Disk diffusion	0	Sirous <i>et al</i> ^[17]
	Iran	2003-2005	100	Disk diffusion	9	Rafeey <i>et al</i> ^[18]
	South Korea	1994-1999	220	Agar dilution	1.4	Kim <i>et al</i> ^[19]
	Malaysia (Malacca)	2009	90	Epsilometer test	0	Goh <i>et al</i> ^[20]
	Pakistan (Karachi)	2008-2013	93	disk diffusion	4.3	Siddiqui <i>et al</i> ^[21]
South America	Brazil (Bragança Paulista)	NA	90	Agar dilution	4	Mendonça <i>et al</i> ^[22]
	Brazil (Bragança Paulista)	NA	138	Agar dilution	13	Godoy <i>et al</i> ^[23]
	Brazil (Sao Paulo)	NA	39	Agar dilution	0	Eisig <i>et al</i> ^[24]
	Brazil (Sao Paulo)	2008-2009	77	Agar dilution and disk diffusion	0	Ogata <i>et al</i> ^[25]
	Brazil (Sao Paulo)	2008-2009	77	Agar dilution	0	Ogata <i>et al</i> ^[26]

stance rates varied but were mostly low (< 5%). *H. pylori* mutations occurring in the *oorD* gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the *porD* gene, including G353A, A356G, C357T, C347T, C347G and C346A, have been indicated to be possibly related to the observed resistance. Regarding levofloxacin resistance, compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the *gyrA* gene for the first time.

Zamani M, Rahbar A, Shokri-Shirvani J. Resistance of *Helicobacter pylori* to furazolidone and levofloxacin: A viewpoint. *World J Gastroenterol* 2017; 23(37): 6920-6922 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i37/6920.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i37.6920>

TO THE EDITOR

We have read with great interest the valuable article by Arslan *et al*^[1], titled "Importance of antimicrobial susceptibility testing for the management of eradication in *Helicobacter pylori* infection". One of the main subjects of the review was the description of the resistance rates of different antibiotics and the potential mechanisms leading to decreased in *Helicobacter pylori* (*H. pylori*) antimicrobial susceptibility. However, the authors should consider clarifying two important issues.

The authors did not allude to the status of *H. pylori* treatment with furazolidone and the resistance to this antibiotic. We have provided existing surveys reporting the resistance of *H. pylori* to furazolidone in Table 1.

The resistance rates have been mostly reported to be lower than 5%; however, these rates can vary geographically. Furazolidone is not used widely in the United States and Europe; therefore, there are not enough data on its efficacy and resistance in these regions.

One of the main reasons for the emergence of resistance is related to the extensive use of furazolidone. In addition, regarding the molecular mechanisms, some genetic mutations have been identified. Mutations occurring in the *2-oxoglutarate:acceptor oxidoreductase (oorD)* gene, including A041G, A122G, C349A(G), A78G, A112G, A335G, C156T and C165T, and in the *pyruvate oxidoreductase (porD)* gene, including G353A, A356G, C357T, C347T, C347G and C346A, are possibly related to the resistance^[2,3]. The *oor* and *por* genes are involved in the generation of acetyl coenzyme A (acetyl-CoA) and succinyl-CoA^[4]. Despite these findings, additional molecular methods are proposed to reach a better understanding of the mechanisms that were mentioned.

Arslan *et al*^[1] accurately documented the mechanism of levofloxacin resistance; *i.e.*, point mutations in the *gyrA* (DNA gyrase) gene were stated to be potentially linked to the resistance. However, to complete their statement, it should be noted that compound mutations of N87A, A88N and V65I at codon Asn-87 were recently observed in the *gyrA* gene for the first time. L45F, A55S, A97V, D91N, R130K and G60S are other possible mutations that need to be assessed in studies with broader sample bases^[5].

REFERENCES

- 1 Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of

- antimicrobial susceptibility testing for the management of eradication in *Helicobacter pylori* infection. *World J Gastroenterol* 2017; **23**: 2854-2869 [PMID: 28522904 DOI: 10.3748/wjg.v23.i16.2854]
- 2 **Su Z**, Xu H, Zhang C, Shao S, Li L, Wang H, Wang H, Qiu G. Mutations in *Helicobacter pylori* *porD* and *oorD* genes may contribute to furazolidone resistance. *Croat Med J* 2006; **47**: 410-415 [PMID: 16758519]
- 3 **Dong F**, Ji D, Huang R, Zhang F, Huang Y, Xiang P, Kong M, Nan L, Zeng X, Wu Y, Bao Z. Multiple Genetic Analysis System-Based Antibiotic Susceptibility Testing in *Helicobacter pylori* and High Eradication Rate With Phenotypic Resistance-Guided Quadruple Therapy. *Medicine* (Baltimore) 2015; **94**: e2056 [PMID: 26632710 DOI: 10.1097/MD.0000000000002056]
- 4 **Hughes NJ**, Clayton CL, Chalk PA, Kelly DJ. *Helicobacter pylori* *porCDAB* and *oorDABC* genes encode distinct pyruvate: flavodoxin and 2-oxoglutarate:acceptor oxidoreductases which mediate electron transport to NADP. *J Bacteriol* 1998; **180**: 1119-1128 [PMID: 9495749]
- 5 **Phan TN**, Santana A, Tran VH, Tran TN, Le VA, Cappuccinelli P, Rubino S, Paglietti B. High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant *Helicobacter pylori* in Vietnam. *Int J Antimicrob Agents* 2015; **45**: 244-248 [PMID: 25499186 DOI: 10.1016/j.ijantimicag.2014.10.019]
- 6 **Sun QJ**, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of *Helicobacter pylori* to antibiotics from 2000 to 2009 in Shanghai. *World J Gastroenterol* 2010; **16**: 5118-5121 [PMID: 20976850 DOI: 10.3748/wjg.v16.i40.5118]
- 7 **Su P**, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of *Helicobacter pylori* isolated in the Southeast Coastal Region of China. *Helicobacter* 2013; **18**: 274-279 [PMID: 23418857 DOI: 10.1111/hel.12046]
- 8 **Ji Z**, Han F, Meng F, Tu M, Yang N, Zhang J. The Association of Age and Antibiotic Resistance of *Helicobacter Pylori*: A Study in Jiaying City, Zhejiang Province, China. *Medicine* (Baltimore) 2016; **95**: e2831 [PMID: 26937912 DOI: 10.1097/MD.0000000000002831]
- 9 **Gehlot V**, Mahant S, Mukhopadhyay AK, Das K, De R, Kar P, Das R. Antimicrobial susceptibility profiles of *Helicobacter pylori* isolated from patients in North India. *J Glob Antimicrob Resist* 2016; **5**: 51-56 [PMID: 27436467 DOI: 10.1016/j.jgar.2015.09.009]
- 10 **Pandya HB**, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial resistance pattern of *Helicobacter pylori* in central Gujarat. *Indian J Med Microbiol* 2014; **32**: 408-413 [PMID: 25297026 DOI: 10.4103/0255-0857.142256]
- 11 **Maleknejad S**, Mojtahedi A, Safaei-Asl A, Taghavi Z, Kazemnejad E. Primary Antibiotic Resistance to *Helicobacter pylori* Strains Isolated From Children in Northern Iran: A Single Center Study. *Iran J Pediatr* 2015; **25**: e2661 [PMID: 26635938 DOI: 10.5812/ijp.2661]
- 12 **Kohanteb J**, Bazargani A, Saberi-Firoozi M, Mobasser A. Antimicrobial susceptibility testing of *Helicobacter pylori* to selected agents by agar dilution method in Shiraz-Iran. *Indian J Med Microbiol* 2007; **25**: 374-377 [PMID: 18087088]
- 13 **Abadi AT**, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in *Helicobacter pylori* strains isolated from the northern population of Iran. *J Microbiol* 2011; **49**: 987-993 [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6]
- 14 **Siavoshi F**, Safari F, Doratotaj D, Khatami GR, Fallahi GH, Mirnaseri MM. Antimicrobial resistance of *Helicobacter pylori* isolates from Iranian adults and children. *Arch Iran Med* 2006; **9**: 308-314 [PMID: 17061600]
- 15 **Fallahi GH**, Maleknejad S. *Helicobacter pylori* culture and antimicrobial resistance in Iran. *Indian J Pediatr* 2007; **74**: 127-130 [PMID: 17337822]
- 16 **Siavoshi F**, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of *H. pylori* isolates to metronidazole and tetracycline--comparison of three 3-year studies. *Arch Iran Med* 2010; **13**: 177-187 [PMID: 20433221]
- 17 **Sirous M**, Mehrabadi JF, Daryani N, Eshraghi S, Hajikhani S, Shirazi M. Prevalence of antimicrobial resistance in *Helicobacter pylori* isolates from Iran. *Afr J Biotechnol* 2010; **9**: 5962-5965
- 18 **Rafeey M**, Ghotaslou R, Nikvash S, Hafez AA. Primary resistance in *Helicobacter pylori* isolated in children from Iran. *J Infect Chemother* 2007; **13**: 291-295 [PMID: 17982716 DOI: 10.1007/s10156-007-0543-6]
- 19 **Kim JJ**, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant *Helicobacter pylori* isolates in a single patient and underestimation of antimicrobial susceptibility testing. *Helicobacter* 2003; **8**: 202-206 [PMID: 12752732]
- 20 **Goh KL**, Navaratnam P. High *Helicobacter pylori* resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. *Helicobacter* 2011; **16**: 241-245 [PMID: 21585611 DOI: 10.1111/j.1523-5378.2011.00841.x]
- 21 **Siddiqui TR**, Ahmed W, Arif A, Bibi S, Khan A. Emerging trends of antimicrobial resistance in *Helicobacter pylori* isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. *J Pak Med Assoc* 2016; **66**: 710-716 [PMID: 27339574]
- 22 **Mendonça S**, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J Jr. Prevalence of *Helicobacter pylori* resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. *Helicobacter* 2000; **5**: 79-83 [PMID: 10849055]
- 23 **Godoy AP**, Ribeiro ML, Benvenuto YH, Vitiello L, Miranda Mde C, Mendonça S, Pedrazzoli J Jr. Analysis of antimicrobial susceptibility and virulence factors in *Helicobacter pylori* clinical isolates. *BMC Gastroenterol* 2003; **3**: 20 [PMID: 12911839 DOI: 10.1186/1471-230X-3-20]
- 24 **Eisig JN**, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. *Helicobacter pylori* antibiotic resistance in Brazil: clarithromycin is still a good option. *Arq Gastroenterol* 2011; **48**: 261-264 [PMID: 22147131]
- 25 **Ogata SK**, Gales AC, Kawakami E. Antimicrobial susceptibility testing for *Helicobacter pylori* isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. *Braz J Microbiol* 2015; **45**: 1439-1448 [PMID: 25763052]
- 26 **Ogata SK**, Godoy AP, da Silva Patricio FR, Kawakami E. High *Helicobacter pylori* resistance to metronidazole and clarithromycin in Brazilian children and adolescents. *J Pediatr Gastroenterol Nutr* 2013; **56**: 645-648 [PMID: 23403439 DOI: 10.1097/MPG.0b013e31828b3669]

P- Reviewer: Ananthakrishnan N, Bao ZJ, Jamali R S- Editor: Ma YJ
L- Editor: A E- Editor: Huang Y





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045